Self-reported responsiveness to direct-to-consumer drug advertising and medication use: results of a national survey by Dieringer, Nicholas J et al.
RESEARCH ARTICLE Open Access
Self-reported responsiveness to
direct-to-consumer drug advertising and
medication use: results of a national survey
Nicholas J Dieringer
1, Lisa Kukkamma
2, Grant W Somes
3 and Ronald I Shorr
1,2,4*
Abstract
Background: Direct-to-consumer (DTC) marketing of pharmaceuticals is controversial, yet effective. Little is known
relating patterns of medication use to patient responsiveness to DTC.
Methods: We conducted a secondary analysis of data collected in national telephone survey on knowledge of and
attitudes toward DTC advertisements. The survey of 1081 U.S. adults (response rate = 65%) was conducted by the
Food and Drug Administration (FDA). Responsiveness to DTC was defined as an affirmative response to the item:
“Has an advertisement for a prescription drug ever caused you to ask a doctor about a medical condition or illness
of your own that you had not talked to a doctor about before?” Patients reported number of prescription and
over-the-counter (OTC) medicines taken as well as demographic and personal health information.
Results: Of 771 respondents who met study criteria, 195 (25%) were responsive to DTC. Only 7% respondents
taking no prescription were responsive, whereas 45% of respondents taking 5 or more prescription medications
were responsive. This trend remained significant (p trend .0009) even when controlling for age, gender, race,
educational attainment, income, self-reported health status, and whether respondents “liked” DTC advertising. There
was no relationship between the number of OTC medications taken and the propensity to discuss health-related
problems in response to DTC advertisements (p = .4).
Conclusion: There is a strong cross-sectional relationship between the number of prescription, but not OTC, drugs
used and responsiveness to DTC advertising. Although this relationship could be explained by physician
compliance with patient requests for medications, it is also plausible that DTC advertisements have a particular
appeal to patients prone to taking multiple medications. Outpatients motivated to discuss medical conditions
based on their exposure to DTC advertising may require a careful medication history to evaluate for therapeutic
duplication or overmedication.
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Background
Considerable controversy surrounds the practice of direct-
to-consumer (DTC) marketing of pharmaceuticals. While
some argue that DTC advertising serves as an educational
resource for patients,[1] others say that DTC advertising
contributes to the medicalization of trivial ailments, and
leads to overuse and misuse of pharmaceuticals[2]. Since
initially allowed by the Food and Drug Administration in
1985,[3] spending on DTC advertising grew steadily over
the following decade. DTC advertising spending acceler-
ated rapidly after 1997, when the Food and Drug Admin-
istration provided draft guidance which described how
sponsors could disseminate information on drugs and bio-
logical products using radio and television [4,5]. Pharma-
ceutical industry expenditures for DTC advertising
increased 330% between 1996 and 2005. In 2005, $4.2 bil-
lion was spent on DTC advertising, which accounted for
14% of all promotional spending for prescription drugs[6].
Expenditures have decreased (in absolute terms) since
2007 following a peak of $5.4 billion in 2006 [7].
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of DTC advertising for individual drugs, 10-35% of sur-
vey respondents say they have discussed medical condi-
tions or medications with their physicians as a result of
DTC advertising[8-10]. Furthermore, patients who speci-
fically request medications during an office visit are
much more likely to receive them than those who do
not[9,11-13].
While much has been written regarding consumer and
physician attitudes toward DTC advertising, less is
known relating patient characteristics, notably medica-
tion use, and responsiveness to DTC advertising. One
survey found that responders to DTC advertising were
more likely to be nonwhite, have lower educational
attainment and lower income,[10] whereas Bell found
that women, as well as persons with a positive attitude
towards DTC advertising, in poorer self-reported health,
and with better self-reported insurance coverage of
medications were more likely to respond to DTC adver-
tising[9]. This survey also found that persons using pre-
scription drugs at the time of the interview were more
likely to be influenced by DTC advertising. To further
investigate the relationship between self-reported medi-
cation use and responsiveness to DTC advertising, we
conducted a secondary analysis of data obtained in an
FDA survey of exposure to, perceptions of, and attitudes
toward DTC advertising.
Methods
Data Source
T h ed a t ac o m ef r o man a t i o n a lt e l e p h o n es u r v e yo f
adults in the U.S., investigating the demographic charac-
teristics and attitudinal effects of DTC prescription drug
advertising of survey respondents[5]. The survey was
conducted by a professional research firm for the Food
and Drug Administration between April and July 1999
to examine attitudes and influence of DTC advertising
of prescription drugs upon the healthcare experience.
The target population for the survey was English speak-
ing consumers aged 18 or older.
Respondents were contacted using random digit dial-
ing methodology and several steps were taken to opti-
mize the response rate. Interviews were scheduled for
varying times of the day in an effort to locate potential
respondents at a convenient time. Respondents were
allowed to schedule “call back” appointments to com-
plete the survey at a more convenient time. Unlimited
call backs (more than 40) were utilized for phone num-
bers that did not initially yield a respondent contact.
Respondents who initially refused to participate, or ter-
minated the interview before completion were contacted
by a mailed follow-up letter as well as two follow-up tel-
ephone solicitations.
Study Population
1081 persons responded to the survey representing a
response rate of 65% (eligible respondents who com-
pleted survey plus ineligible respondents divided by the
total contacted minus bad telephone numbers). From
these, 310 persons who had not been exposed to DTC
prescription drug marketing in the three months prior
to the survey, and therefore did not answer the question
of interest, were excluded. Table 1 describes those per-
sons excluded from the analysis. Thus our study popula-
tion included 771 persons.
Main Measures
“Responsiveness to DTC drug marketing” was defined as
an affirmative response to the survey item: “Has an
advertisement for a prescription drug ever caused you
to ask your doctor about a medical condition or illness
of your own that you had not talked to a doctor about
Table 1 Characteristics of Respondents Not Exposed to
DTCA, Excluded From Study
Characteristic Prevalence
Age
Less than 65 years 72.0
65 years or older 28.0
Gender
Male 35.2
Female 64.8
Race
White 66.5
Non-white 33.5
Marital Status
Married 49.7
Single, widowed, divorced, other 50.3
Educational Attainment
College graduate or higher 23.2
Some college or less 76.8
Annual Income
Less than $35,000 57.9
$35,000 or more 42.1
Time since last visit to physician
Within one month 40.7
More than one month 59.3
Self-reported health
Excellent 17.8
Very Good 29.1
Good 27.2
Fair 18.1
Poor 7.8
Mean # of Rx drugs in past 6 months 2 (S.D. 1.6)
Mean # of OTC drugs in past 6 months 1.2 (S.D. 1.2)
n = 310
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using the self-reported number of prescription drugs,
and OTC drugs used within the six month period prior
to the survey.
Covariates
Covariates were also determined from the survey. These
included gender, race, income, marital status, date of
last physician visit, self-reported health, self-reported
knowledge about health and medications, and attitude
toward DTC drug advertisements. Self-reported health
was assessed with a single item using a five point scale
ranging from 1 ("excellent” health) to 5 ("poor” health).
Self-reported knowledge about health and medications
was assessed with a single item using a four point scale
ranging from 1 ("extremely” knowledgeable) to 5 ("not
at all” knowledgeable). Attitude toward DTC drug
advertisements was assessed with a single item asking
how much the respondent “liked” DTC advertising with
responses on a five point scale ranging from 1 ("strongly
agree”) to 5 ("strongly disagree”).
Statistical Analysis
We used T-test and chi-square tests for univariate ana-
lyses. For multivariate analysis, we used logistic regres-
sion controlling for covariates. These covariates
included age, gender, race, educational attainment, mari-
tal status, income, self-reported health status, self-
reported knowledge of medicines and health, and atti-
tude toward DTC advertising. We performed all ana-
lyses using SAS version 9.1 (SAS Institute Inc, Cary,
NC). All p-values were 2-sided and a was set at .05.
Results
Characteristics of the Study Sample
The average respondent’s age was (mean ± s.d.) 46.1 ±
15.7 years, 64% were female, and 81% were white. Forty-
two percent had completed at least a college degree and
57% were married at time of interview. On average,
respondents had encountered 2.4 ± 1.3 modes of deliv-
ery of DTC prescription drug advertising (e.g. maga-
zines, television, newspaper, etc.) in the three months
prior to the interview. Respondents’ mean score for how
much they “liked seeing” these advertisements was 2.7 ±
1.4. The mean response for respondents’ self-reported
knowledge of medications and health matters in general
was 2.6 ± 0.7. Similarly, mean response for respondents’
self-reported health status was 2.4 ± 1.1 see Table 2.
Relationship between Respondent Characteristics and
Responsiveness to DTC Marketing
Overall, 195 (25.3%) respondents answered affirmatively
to our variable of interest, indicating that they had
initiated discussion of a medical problem with their
physician based on DTC advertising. Compared to
respondents who denied discussing medical problems
with their physicians based on DTC advertising, respon-
dents who used DTC advertising as a foundation for
discussing a new health problem with their physician
were older, possessed less educational attainment, and
“liked” seeing DTC prescription drug advertisements.
Gender, race, marital status, self-reported health status,
self-reported knowledge about health and medications,
a n di n c o m ew e r en o ts i g n i f i c a n t l ya s s o c i a t e dw i t ht h e
primary endpoint (see Table 2).
Relationship between Self-Reported Prescription
Medication Use and Responsiveness to DTC Marketing
The mean number of prescription drugs used in the six
months prior to the survey was 2.4 ± 1.6. Of 108 per-
sons using no prescription medications, 9 (8.3%) were
responsive to DTC advertisements. Of 131 persons
using five or more prescription medicines, 50 (38.1%)
were responsive to DTC advertisements. There was a
strong trend (p < .0001) in the relationship between
number of prescription medications used and respon-
siveness to DTC advertisements. This association
remained highly significant (p = .0009) even when con-
trolling for demographics, self-reported health status,
educational attainment, race, marital status, self-reported
knowledge of medications and health, number of OTC
medications used, income, and attitude toward DTC
advertisements see Figure 1.
Relationship between Self-Reported OTC Medication Use
and Responsiveness to DTC Marketing
The average number OTC drugs used in the six months
prior to the survey was 1.8 ± 1.4. Of 136 persons using
no OTC medications, 44 (32.3%) were responsive to
DTC. Of 61 persons using five or more OTC medicines,
20 (32.7%) were responsive to DTC. There was no linear
trend in either univariate (p = .54.) or multivariate (p =
.76) relationship between number of OTC medications
used and responsiveness to DTC see Figure 2.
Discussion
O u rd a t ai n d i c a t et h a tac r o ss-sectional relationship
exists between number of prescription drugs used and
“responsiveness” to DTC advertising. This strong linear
relationship remains even when controlling for demo-
graphic and socioeconomic variables and self-reported
health. Overall, 25.3% of respondents were motivated by
DTC advertising to initiate discussion regarding new
health problems. Among respondents taking no pre-
scription medications, fewer than 10% were motivated
by DTC advertising. Conversely, among respondents
taking five or more prescription medicines, nearly 40%
were motivated.
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identified 13 surveys, primarily for lay publications,
which attempted to assess consumer behavior related
DTC advertising[8]. Since that time several additional
surveys have been published in the medical and scienti-
fic literature[10,14-16]. In these studies, the proportion
of respondents who reported being influenced by DTC
advertising to seek medical care ranged from 10.5 to
35%. Although there is some variation in how each
survey defines responsiveness to DTC advertising, our
finding that 25% of respondents had discussed a new
medical condition with a physician based on DTC
advertising is generally consistent with others.
Our results confirm those of previous studies, [10,17]
which identify older age, lower educational attainment
and a positive attitude towards DTC advertising as fac-
tors associated with responsiveness to DTC advertising
[9,10]. In contrast to other studies, [14,18] we did not
Table 2 Sample Characteristics by Responsiveness to DTC Advertising
Covariate Prevalence Proportion responsive to
DTC advertising
Multivariate association with responsiveness to DTC
advertising (OR, 95% CI)
Age
Less than 65 years 85.9 23.2 2.5 (1.5-4.1)
65 years or older 14.1 37.6
Gender
Male 36.1 22.2 1.0 (.7-1.5)
Female 63.8 27.3
Race
White 82.6 24.5 .7 (.4-1.0)
Non-white 17.4 31.1
Marital Status
Married 57.5 25.5 1.1 (.7-1.6)
Single, widowed, divorced, other 42.1 25.0
Educational Attainment
College graduate or higher 57.8 28.9 .7 (.4-1.0)
Some college or less 42.1 20.3
Annual Income
Less than $35,000 48.6 25.8 1.2 (.8-1.9)
$35,000 or more 51.3 24.8
Self-reported health
Excellent 23.2 13.4 1.1 (1.0-1.4)
Very Good 41.4 25.1
Good 22.1 32.9
Fair 11.9 28.5
Poor 4.4 44.1
Time since last visit to physician
Within one month 59.6 27.4 .9 (.6-1.4)
More than one month 40.4 22.2
Self-reported knowledge about health
and medications
Extremely knowledgeable 8.8 22.1 1.0 (.8-1.3)
Very knowledgeable 30.0 25.5
Somewhat knowledgeable 58.2 25.4
Not at all 3.0 26.1
Like seeing advertisements for
prescription drugs
Strongly agree 20.4 41.6 1.4 (1.2-1.6)
Agree somewhat 31.0 24.4
Neither agree or disagree 20.8 20.7
Disagree 10.9 18.1
Strongly disagree 16.9 15.5
n = 771
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reported health status and DTCA.
We found that a cross-sectional relationship exists
between responsiveness to DTC and self-reported use of
prescription, but not OTC, drugs. Because there was a
trend towards poorer self-reported health and respon-
siveness to DTC, is plausible that users of prescription
medications represent a sicker population, and one that
may be more attuned to the messages conveyed in DTC
advertising. Alternatively, because DTC advertising lar-
gely focuses on prescription medications, persons who
a r er e s p o n s i v et oD T Cm a yh a v ea p p r o a c h e dt h e i rp r e -
scribers based on information in DTC, resulting in more
prescription, rather than OTC, use. Bell and colleagues
found that current users of prescription drugs were
more likely to be influenced by DTC advertising,[9] but
did not quantify the number of prescriptions, and lim-
ited their sample to one county in California.
Our investigation confirms results of a smaller study
of Minnesotans by Schommer et al. [15] that found pre-
scription medication use to be statistically greater in
respondents who were responsive to DTC advertising
than those who were not. Similar to our results, no
significant difference was found in the number of OTC
medications used by responsive versus unresponsive
patients.
The main strength of our study is that the source of
data comes from a large nationally representative sample
with a high response rate. Furthermore, unlike some
other studies, OTC as well as prescription drug use was
ascertained. Our study has several limitations. First,
these data were collected in 1999. Penetration and
awareness of DTC advertising, as well as types of media
outlets (e.g. internet), have increased considerably in
subsequent years. Despite this, however, we are encour-
aged by similarities in regard to attitudinal, socioeco-
nomic and demographic predictors of susceptibility to
DTC advertising demonstrated in more recent surveys,
[14,15] and likewise feel that the relationship between
number of prescription drugs used and susceptibility to
DTC advertising should be no less true today. Second,
this is a secondary analysis of FDA data originally col-
lected to investigate attitudinal and demographic effects
toward DTC advertising; thus, rigorous ascertainment of
medication use was not included. Although the self-
reported medication use measure is a limitation, it has
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Figure 1 Proportion of respondents who were responsive to direct-to-consumer (DTC) advertising, by number of self-reported
prescription medications used in six months prior to study. The number of respondents in each category is embedded in the bars.
Dieringer et al. BMC Health Services Research 2011, 11:232
http://www.biomedcentral.com/1472-6963/11/232
Page 5 of 7been used in a previous survey of DTC advertising,[15]
and has been found to be congruent with pharmacy pre-
scription data[19,20].
The cross-sectional nature of this study does not allow
for unequivocal statements regarding the direction of
causality. Although this relationship could be explained
by physician compliance with patient requests for medi-
cations, it is also plausible that DTC advertisements
have a particular appeal to patients prone to taking mul-
tiple medications. Finally, the main measure in this
study specifically asks about initiating discussion with a
physician about a new medical problem and thus may
not have captured those patients who use DTC adver-
tisements to prompt discussion of previously discussed
problems, or those patients who may have discontinued
a medication due to information contained in DTC
advertisements.
Conclusion
There is a strong cross-sectional relationship between
the number of prescription, but not OTC, drugs used
and responsiveness to DTC advertising. Although this
relationship could be explained by physician compliance
with patient requests for medications, it is also plausible
that DTC advertisements have a particular appeal to
patients prone to taking multiple medications. Outpati-
ents motivated to discuss medical conditions based on
their exposure to DTC advertising may require a careful
medication history to evaluate for therapeutic duplica-
tion or overmedication.
Further research needs to be performed to understand
this population’s eagerness to utilize prescription drugs
and to determine if this eagerness transcends to utiliza-
tion of other health care resources. Clearly, these DTC
advertisements are powerful motivators. Perhaps they
could be used to enhance evidence-based prescribing
and advance public health.
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